Clinical Trial: Studying Gene Expression in Samples From Patients With Rhabdoid Tumors
Study Status: Completed
Recruit Status: Completed
Study Type: Observational
Official Title: Determination of the Frequency of BRG1 and BRM Loss in Rhabdoid Tumors
Brief Summary:
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and find biomarkers related to cancer. It may also help doctors find better ways to treat cancer.
PURPOSE: This research trial studies gene expression in samples from patients with rhabdoid tumors.
Detailed Summary:
OBJECTIVES:
- To determine if BRM is silenced in the majority, if not all, rhabdoid tumors by immunohistochemistry in primary tumors.
- To determine if BRG1 is silenced in the majority, if not all, rhabdoid tumors by immunohistochemistry in primary tumors.
- To determine if GATA1 and/or HDAC2 is overexpressed in the same tumors that lack BRM expression.
- To determine if BRM promoter polymorphisms correlate with loss of BRM expression in primary rhabdoid tumors.
- To determine how BRG1 is silenced in primary rhabdoid tumors by sequencing BRG1 exons in genomic DNA derived from frozen samples.
OUTLINE: Archived tumor tissue samples are analyzed for BRM, BRG1, GATA1, and/or HDAC2 expression by immunohistochemistry. BRM- and BRG1-negative samples are also analyzed.
Sponsor: Children's Oncology Group
Current Primary Outcome:
- Absence or presence BRG1 and BRM expression in rhabdoid tumors
- Mechanism of suppression of BRG1 and BRM genes
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Children's Oncology Group
Dates:
Date Received: March 10, 2012
Date Started: March 2012
Date Completion:
Last Updated: July 13, 2016
Last Verified: July 2016
